BIP Capital Partners

Skip to content

HOME
About us
- OUR TEAM
- OUR HISTORY
- ESG
- BIP IV
investment approach
- INVESTMENT APPROACH
- INVESTMENT CHARACTERISTICS
portfolio
- SELECTED INVESTMENTS
- SELECTED EXITS
News
CONTACT

Enzymotec reports 3rd quarter 2014 unaudited financial results

Post navigation

Previous PostBIP invests in lifebrain AG, an Austrian-based medical diagnostic laboratory group Next PostMoleskine announces first nine months 2014 results

© BIP Group Luxembourg 2025

Stay in touch with us, leave your email